Notal Vision Monitoring Center

The future of retinal care isn't just about longer-lasting therapies, it's also about better data between office visits.

A newly published peer-reviewed study in Medicina MDPI demonstrates that Home OCT monitoring can serve as a safety net for patients with neovascular AMD receiving standard care.

Key findings:
• 65% of treatment intervals showed persistent or recurrent retinal fluid before the next scheduled office visit.
• Disease activity was detected an average of 32 days earlier than the next routine visit.
• Nearly 70% of these intervals had the potential for an earlier clinical evaluation within currently labeled treatment intervals.

For retina specialists, this means greater confidence that disease reactivation won't go unnoticed between visits.

For pharmaceutical innovators developing long-acting anti-VEGF therapies and gene therapies, it highlights an important opportunity: treatment durability delivers its greatest value when paired with continuous disease surveillance.

The publication further reinforces that the Home OCT monitoring program complements, not replaces, standard retinal care by providing physicians with objective structural retinal information between office visits, enabling timely clinical evaluation when disease activity returns.

As therapies become more durable, monitoring should become more continuous.

The publication adds to the growing body of evidence supporting Home OCT monitoring and should help advance payer coverage, ensuring that patients who can benefit from this technology have access to the care they need.

Read the paper: https://notalvision.info/4wheE8z

Home OCT is more than a device in a patient’s home. It is an integrated care model designed to support wet AMD monitoring between office visits.

In this Retina Synthesis discussion, Prof. Anat Loewenstein highlights what makes the model meaningful: physician oversight, patient support, AI-based analysis, compliance monitoring, and flexible physician alerts.

That system-level approach matters as treatment intervals continue to evolve. With longer-acting therapies, physicians need better visibility into which patients are stable over time and which patients may need closer attention.

Near-daily home OCT can provide a more complete view of disease activity between visits, while validated AI helps make that volume of data clinically usable.

Listen to the full discussion here: https://notalvision.info/3QzKXAp

“The home eye exam” is becoming a bigger part of the conversation in eye care, and a recent AI in Eye Care article offers a helpful look at what is already out there.

The future of retinal care includes more information between regularly scheduled office visits, whether through ForeseeHome monitoring for patients at risk of progression from intermediate dry AMD to wet AMD, or SCANLY Home OCT for patients already diagnosed with wet AMD.

Together, these technologies reflect an important shift in eye care: from relying only on single time-point assessments to supporting physicians with longitudinal information from the patient’s home.

Read the full article: https://notalvision.info/4uNY7c0